Menu Search
Equities

EGF Theramed Health Corp

EVAHF:PKC

EGF Theramed Health Corp

Actions
  • Price (USD)0.0825
  • Today's Change0.00 / 0.00%
  • Shares traded725.00
  • 1 Year change-53.02%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 20:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

EGF Theramed Health Corp. is a Canada-based company. The Company is engaged in developing products, technologies, and diagnostic tools focused on personalized medical care including research with natural health and wellness products. Its portfolio includes Pharmadelic Labs, and Green Parrot Labs. Pharmadelic Labs is a biotech company focusing on improving and patenting engineering processes for the biosynthesis of compounds-primarily psilocybin, the psychoactive component of magic mushrooms. Green Parrot Labs is a Caribbean-based company focusing on research into psilocybin and establishing health centres dealing with treatment-resistant conditions. Psilocybin is one of the psychedelics for the treatment of conditions such as treatment-resistant depression, anxiety, post-traumatic stress disorder (PTSD) and depression. Its subsidiaries include Hemp Extraction Technology Corp., Western Agri Supply Solutions Inc., Medical Green Natural List Corp., and Seedadelic Health Services Corp.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-310.05k
  • Incorporated2011
  • Employees--
  • Location
    EGF Theramed Health CorpSuite 1600 - 609 Granville StreetPacific CentreP.O. Box 10068VANCOUVER V7Y 1C3CanadaCAN
  • Phone+1 (604) 780-3311
  • Fax+1 (604) 780-3311
  • Websitehttps://www.egftheramedhealth.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.